Neuropeptide Y: Side Effects

Important Safety Notice#

Neuropeptide Y is not approved for therapeutic use. Safety data from clinical trials is limited to a single small RCT with intranasal delivery. NPY is a potent endogenous peptide with effects on appetite, cardiovascular function, and stress response that could present safety concerns.

Clinical Trial Safety Data#

In the Sayed et al. (2020) RCT, single-dose intranasal NPY (6.8 mg) was well tolerated in 30 MDD patients with no significant adverse events reported. However, the study was small and assessed effects only over 48 hours.

Known Pharmacological Effects with Safety Implications#

Appetite Stimulation#

NPY is one of the most potent known appetite-stimulating molecules. Central NPY signaling through Y1 and Y5 receptors in the hypothalamus powerfully drives food intake. Chronic or repeated intranasal NPY administration could potentially increase appetite and body weight.

Cardiovascular Effects#

NPY acts as a co-transmitter with norepinephrine in sympathetic nerves and is a potent vasoconstrictor through Y1 receptors on vascular smooth muscle. This raises concerns for individuals with hypertension, coronary artery disease, or other cardiovascular conditions.

Seizure Threshold#

NPY has complex effects on seizure activity, with Y1 activation being proconvulsant and Y2 activation being anticonvulsant in some models. The net effect of intranasal NPY on seizure threshold in humans is unknown.

Drug Interactions#

No formal drug interaction studies have been conducted. Key theoretical interactions include effects on blood pressure (antihypertensives), appetite (weight management medications), and NPY metabolism (DPP-IV inhibitors like sitagliptin may alter NPY degradation).

Safety Profile Context#

Neuropeptide Y belongs to the Neuropeptide category of research peptides. Understanding the side effect profile of Neuropeptide Y is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Neuropeptide Y. Side effect severity and frequency are based on available clinical data.

Appetite stimulation#

Severity: moderate | Frequency: expected

NPY is one of the most potent orexigenic peptides. Intranasal or central NPY administration may increase appetite and food intake.

Nasal irritation#

Severity: mild | Frequency: common

Mild nasal irritation associated with intranasal delivery, consistent with other intranasally administered peptides.

Cardiovascular effects#

Severity: moderate | Frequency: theoretical

NPY is a potent vasoconstrictor through Y1 receptors on vascular smooth muscle. Peripheral cardiovascular effects may occur at higher doses.

Contraindications#

The following contraindications have been identified for Neuropeptide Y based on available research and pharmacological considerations:

• Not approved for human use by any regulatory agency
• Caution in individuals with cardiovascular disease (NPY causes vasoconstriction via Y1 receptors)
• Caution in individuals with eating disorders or obesity (NPY stimulates appetite)

Individuals with any of these conditions should not use Neuropeptide Y without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Neuropeptide Y:

• Potential interaction with antihypertensive medications (NPY causes vasoconstriction)
• May interact with appetite-modulating medications (NPY is orexigenic)
• Theoretical interaction with DPP-IV inhibitors (which would slow NPY metabolism)

Drug interaction studies for Neuropeptide Y remain limited. Researchers should exercise caution when combining Neuropeptide Y with other compounds and consult relevant pharmacological references.

Related Reading#

• Neuropeptide Y overview and research guide
• Neuropeptide Y dosing protocols
• Neuropeptide Y risks and legal status